Patient's weight | Rivaroxaban dose* |
2.6 to <3 kg | 0.8 mg 3 times daily |
3 to <4 kg | 0.9 mg 3 times daily |
4 to <5 kg | 1.4 mg 3 times daily |
≥5 to <7 kg | 1.6 mg 3 times daily |
≥7 to <8 kg | 1.8 mg 3 times daily |
8 to <9 kg | 2.4 mg 3 times daily |
9 to <10 kg | 2.8 mg 3 times daily |
10 to <12 kg | 3 mg 3 times daily |
12 to <30 kg | 5 mg twice daily |
30 to <50 kg | 15 mg once daily |
≥50 kg | 20 mg once daily¶ |
VTE: venous thrombosis and thromboembolism; LMWH: low molecular weight heparin; UFH: unfractionated heparin.
* Where available, rivaroxaban oral suspension should be used for patients weighing <30 kg; rivaroxaban tablets or an oral suspension may be used for patients ≥30 kg. Tablets should not be split to achieve a lower dose.
¶ This dose differs slightly from the recommended dose for treatment of VTE in adult patients, in whom a twice-daily dosing regimen is used for the first 21 days of therapy. In addition, adult patients can start rivaroxaban without initial parenteral therapy. If this approach is used in a pediatric patient weighing ≥50 kg (ie, if the patient is not treated with initial parenteral therapy), then the adult dosing regimen should be used. This consists of rivaroxaban 15 mg twice daily for 21 days, followed thereafter by 20 mg once daily.Do you want to add Medilib to your home screen?